An experimental breast cancer drug from Seattle Genetics is headed for FDA review after the company reported a pivotal clinical trial met its main goals.
The company has been testing tucatinib as a treatment for advanced or metastatic breast cancer with abnormally high levels of a protein called human epidermal growth factor receptor 2 (HER2), which promotes the aggressive spread of cancer cells.
Seattle Genetics (NASDAQ: SGEN) on Monday announced preliminary study results and said that its targeted therapy, given in combination with two chemotherapies, trastuzumab and capecitabine, met the primary and secondary goals set for the trial. The successful… Read more »
UNDERWRITERS AND PARTNERS
